{"id":6668,"date":"2024-11-21T14:56:53","date_gmt":"2024-11-21T13:56:53","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6668"},"modified":"2025-04-28T21:55:37","modified_gmt":"2025-04-28T19:55:37","slug":"tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or-metastatic-nasopharyngeal-cancer-a-multicenter-phase-3-trial-rationale-309","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or-metastatic-nasopharyngeal-cancer-a-multicenter-phase-3-trial-rationale-309\/","title":{"rendered":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6668","publication","type-publication","status-publish","hentry","disease_state-nasopharyngeal-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6668"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}